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Summary
We identify a novel alternative TrkA splice variant, TrkAIII, with deletion of exons 6, 7, and 9 and functional extracellular
IG-C1 and N-glycosylation domains, that exhibits expression restricted to undifferentiated early neural progenitors, human
neuroblastomas (NBs), and a subset of other neural crest-derived tumors. This NGF-unresponsive isoform is oncogenic
in NIH3T3 cells and promotes tumorigenic NB cell behavior in vitro and in vivo (cell survival, xenograft growth, angiogenesis)
resulting from spontaneous tyrosine kinase activity and IP3K/Akt/NF-B but not Ras/MAPK signaling. TrkAIII antagonizes
NGF/TrkAI signaling, which is responsible for NB growth arrest and differentiation through Ras/MAPK, and its expression
is promoted by hypoxia at the expense of NGF-responsive receptors, providing a mechanism for converting NGF/TrkA/
Ras/MAPK antioncogenic signals to TrkAIII/IP3K/Akt/NF-B tumor-promoting signals during tumor progression.
Introduction kinase (Tk) activity upon dimerization (Kaplan et al., 1991; Mea-
kin and Shooter, 1991) and initiates intracellular signal transduc-
Neurotrophin tyrosine kinase receptor type 1 (TrkA), a member tion by autophosphorylating Y490, Y674/675, Y751, and Y785
of the tyrosine kinase neurotrophin receptor family that includes tyrosine residues, which act as phosphorylation-dependent
TrkB and TrkC, is the preferred receptor for nerve growth factor binding sites for Shc (Y490), Grb-2/SOS (Y674/675), and FRS-2
(NGF) and is critical for development and maturation of central (Y490) adaptor proteins, the inositol phosphate 3 kinase (IP3K)
and peripheral nervous systems, regulating proliferation, differ- subunit p85 (Y751), and PLC (Y785). These interactions in-
entiation, and programmed cell death (Bibel and Barde, 2000; duce signal transduction through Ras/MAPK, inositol phos-
Oppenheim, 1991; Hempstead et al., 1991; Martin-Zanca et al., phate, and/or PKC, which mediate NGF effects on proliferation,
1989; Klein et al., 1991; Kaplan et al., 1991; Meakin and Shooter, differentiation, and apoptosis (Obermeier et al., 1993a, 1993b,
1991). 1994; Kaplan and Stephens, 1994; Yao and Cooper, 1995;
The 25 kb human TrkA gene maps to chromosome 1q21- Green and Kaplan, 1995; Segal et al., 1996; Cunningham et al.,
q22 (Weier et al., 1995), is organized into 17 exons (Greco et
1997; Meakin et al., 1999).
al., 1996), with exon 9 alternatively spliced, producing TrkAI and
Oncogenic TrkA activation by point mutation, deletion, orII isoforms (Barker et al., 1993), and encodes a transmembrane
novel chimera formation due to chromosomal rearrangementsreceptor that is comprised of extracellular, transmembrane, and
results in spontaneous ligand-independent receptor dimeriza-intercellular domains. The extracellular domain contains two cyste-
tion and activation, constitutive adaptor protein binding, chronicine-rich regions interrupted by a leucine-rich domain and two im-
signal transduction, and cellular transformation. Activated TrkAmunoglobulin-like IGC1 and IGC2 regions (Urfer et al., 1995; Win-
oncogenes have been associated with several human malignan-disch et al., 1995; Holden et al., 1997; Arevalo et al., 2000).
cies, including colon, thyroid, and prostate carcinomas andTransmembrane and juxtamembrane domains are critical for
acute myeloid leukemia (Oskam et al., 1988; Martin-Zanca etsignal internalization and transduction (Peng et al., 1995; Mon-
shipouri et al., 2000). The intercellular domain exhibits tyrosine al., 1986; Coulier et al., 1990; Borello et al., 1994; George et
S I G N I F I C A N C E
Identification of the novel TrkAIII splice variant unveils an alternative splice mechanism for inducing ligand-independent TrkA signaling
and antagonizing signals from NGF-responsive receptors. The restricted pattern of TrkAIII expression that is observed suggests a
mechanism of physiological relevance to normal neural progenitors, conserved but subverted to pathological importance in NB,
that challenges current concepts of an exclusively tumor-suppressing role for TrkA in this tumor type. Stimulation of alternative TrkAIII
splicing by hypoxia, as well as the capacity of TrkAIII to promote a more angiogenic and stress-resistant phenotype, suggests a
role in protection against hypoxic conditions, while providing an important epigenetic mechanism to promote TrkAIII involvement
in tumor progression and a potential target for therapeutic intervention.
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al., 1998; Greco et al., 1992, 1995; Butti et al., 1995; Reuther TrkAIII expression is relatively specific but not
exclusive to neuroblastomaet al., 2000; Arevalo et al., 2001).
Neuroblastoma (NB), a highly aggressive malignant child- TrkAIII mRNA expression in human primary NB samples was
confirmed by RT-PCR/Southern blot using TrkA-specific prim-hood tumor of neural crest origin (reviewed in Pahlman and
Hedborg, 2000), associates with noncoding TrkA gene polymor- ers spanning cDNA sequences including exons 5 to 8 (see the
Supplemental Data at http://www.cancercell.org/cgi/content/phisms and point mutations (Scaruffi et al., 1999) but not with
genetic oncogenic TrkA activation. NB cell lines exhibit general full/6/4/347/DC1/). Primers generated two RT-PCR products
of approximately 850 bp and 570 bp from 1 g total RNAs,NGF unresponsiveness (Azar et al., 1990), and TrkA expression
exhibits an inverse relationship to NB aggressiveness, consis- determined to be within the linear range by comparative 15-,
25-, 35-, and 50-cycle RT-PCR amplification (Figure 2 and datatent with a potential marker of good prognosis (Nakagawara et
al., 1992; Nakagawara, 2001). A potential tumor-suppressing not shown). In Southern blots, both products hybridized to a
TrkA exon 8 probe, whereas only the 850 bp product hybridizedrole for TrkA in NB is supported by TrkA gene transduction in
NB cells, which restores NGF responsiveness, characterized by to a TrkA exon 6–7 probe, consistent with TrkA (I/II) identity for
the 850 bp product and TrkAIII identity for the 570 bp productTrkA activation and binding of phosphorylated Shc, Grb-2/SOS,
FRS-2, PLC-1, and p85 and signal transduction through IP, (Figure 2A). Confirmation that products reflected individual
mRNA species was obtained using additional primer sets (seeRas/MAPK, and PKC, and results in differentiation, growth ar-
rest, apoptosis, and inhibition of angiogenesis (Matsushima and the Supplemental Data) spanning a similar region, which also
generated two major RT-PCR products consistent with TrkAI/IIBogenmann, 1990; Azar et al., 1990; Lavenius et al., 1995; Yao
and Cooper, 1995; Lucarelli et al., 1997; Edsjo et al., 2001; and TrkAIII (data not shown). TrkAIII identity was further con-
firmed by direct sequence analysis of several independent 570Sugimoto et al., 2001; Eggert et al., 2002).
Here, we challenge the concept of an exclusively tumor- bp products (data not shown). The NB RNAs available for this
study were insufficient for Northern blot analysis. However, hu-suppressing, nononcogenic role for TrkA in NB by unveiling a
novel hypoxia-regulated mechanism for oncogenic TrkA activa- man primary NBs have previously been shown to contain an
additional lower-sized species other than 3.2 kb TrkAI by North-tion in NB cells characterized by generation of a novel constitu-
tively active TrkAIII splice variant that exhibits oncogenic proper- ern blotting (Nakagawara et al., 1992), consistent with TrkAIII
expression.ties, antagonizes antioncogenic NGF/TrkAI signaling, and is
expressed by primary human NBs. Densitometric analysis of the ratio between TrkAI/II and
TrkAIII RT-PCR products (i.e., the TrkA I/II densitometric value
divided by the TrkAIII densitometric value) in NB samplesResults
grouped by disease stage (I–IV, international NB staging system)
revealed that TrkAI/II to TrkAIII ratios in stage I and II tumorsIdentification, cloning, and sequence analysis
of the novel TrkAIII splice variant expressed (5.3  3.89 and 7.0  3.6, respectively) were higher those in
stage III and IV tumors (1.3  2.0 and 1.4  1.4, respectively)by SH-SY5Y cells
Direct sequence comparison of full-length coding TrkA cDNAs (Figure 2B). Indeed, the mean (SD) TrkAI/II to TrkAIII densito-
metric ratio in combined low stage (I and II) samples of 6.21 cloned from human SH-SY5Y NB cells, by reverse transcriptase-
PCR (RT-PCR) using TrkA-specific primers (Experimental Pro- 3.64 (n  11) was significantly greater (p  0.001, Student’s t
test; p  0.02, Mann-Whitney test) than the ratio in combinedcedures), revealed a novel TrkA isoform lacking exons 6, 7, and
9 sequence, other than TrkAI and TrkAII (Martin-Zanca et al., high stage (III and IV) samples (1.335  1.66; n  13). Accord-
ingly, TrkAIII predominated over TrkA (I/II) RT-PCR products in1989; Barker et al., 1993), which we have named TrkAIII (Figure
1A). Omission of exons 6, 7, and 9 sequence did not introduce one of eleven stage I and II tumors and six out of thirteen stage
III and IV tumors (Figure 2B). Several high stage tumors exhibiteda frameshift or novel stop codon. Deletions or point mutations
were not detected in TrkA gene sequence, examined by direct relatively low-level TrkA(I/II) expression, with three also exhib-
iting Nmyc amplification (Figure 2A), supporting reports of anPCR sequencing of products generated from purified SH-SY5Y
genomic DNA, using primers (see the Supplemental Data at inverse relationship between Nmyc amplification and TrkA(I/II) ex-
pression (Nakagawara et al., 1992; Nakagawara, 2001). Together,http://www.cancercell.org/cgi/content/full/6/4/347/DC1/)
spanning the intron/exon 5 to exon 8/intron splice junctions these data suggest that, in contrast to TrkA(I/II), TrkAIII expression
may relate to disease progression.(data not shown) (Greco et al., 1996). TrkA exon 6–7 omission
predicts loss of amino acids 192–284, encoding extracellular In other neural crest-derived tumor tissues, comparatively
low-level expression of TrkAIII together with TrkA(I/II) was de-immunoglobulin-like IG-C1 and several functional N-glyco-
sylation domains (Martin-Zanca et al., 1989) and a valine addi- tected in a medullary thyroid tumor and in two of three prostate
tumors, whereas neither TrkA(I/II) nor TrkAIII was detected intion at the novel exon 5/8 splice junction (Figure 1A).
In Northern blots, SH-SY5Y cells expressed two TrkA spe- melanomas. In neural crest-unrelated tumors, TrkA(I/II) but not
TrkAIII expression characterized six human pituitary adenomas,cies of approximately 2.8 and 3.2 kb, both of which hybridized
to a TrkA exon 8 probe, with the larger but not smaller species whereas neither was detected in tumors of the breast, colon,
and stomach (Figure 2C).hybridizing also with a TrkA exon 6–7 probe (Figure 1B). Western
blots of anti-TrkA immunoprecipitates revealed low-level ex- In nontumor tissues, TrkA(I/II) without TrkAIII expression
characterized normal human fetal and adult brain- and neuralpression of two TrkA species of approximately 140 kDa and
100 kDa, in SH-SY5Y cells, consistent with TrkAI/II (140 kDa) crest-derived adrenal medulla and dorsal root ganglia, whereas
neither TrkA(I/II) nor TrkAIII was detected in nonneural normaland TrkAIII (100 kDa) (Figure 1B), at an approximate ratio of 3:1
(Figures 1B and 8B; see Figure 3B for transfected TrkAI and breast, colon, and stomach tissues (Figure 2C).
To further investigate TrkAIII in cell subsets, expression wasTrkAIII).
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Figure 1. TrkAIII is devoid of exons 6, 7, and 9
A: Schematic TrkAI representation indicating extracellular IG-C1 and -C2, transmembrane (TM) tyrosine kinase (TK) domains, and relative exons 6, 7 (Ex
6–7), and 9 (Ex 9) positions. Partial exon 5 (black), 8 (blue), 10 (brown), complete exon 6 (red), 7 (green), 9 (purple), and novel unique TrkAIII exon 5/8 and
exon 8/10 splice junction (TrkAII and AIII) cDNA and amino acid sequences are provided (IG-C1 domain is underlined; N-glycosylation sites are boxed).
B: Northern blot (left) of SH-SY5Y TrkA mRNA species (arrows) hybridizing to TrkA exon 8 (ex 8) and exon 6–7 (ex6/7) probes (28S and 18S indicated). Western
blot (right) of 140 and 100 kDa TrkA species immunoprecipitated from SH-SY5Y cells (2 mg protein) by anti-TrkA but not preimmune IgG.
analyzed in both established and primary normal and tumor cell tubulin (Figure 2E) and NeuN (data not shown). Neither TrkA(I/II)
nor TrkAIII expression was detected in mouse NIH3T3 or humancultures. In tumor cell cultures, TrkA(I/II) and TrkAIII coexpres-
sion characterized the human (IMR32, SH-SY5Y, SK-N-AS, MRC-5 fibroblasts (data not shown). These observations suggest
relatively restricted TrkAIII expression to neural crest-derivedKCNR, SK-N-SH [S and N], LA-N-5, SK-N-BE) and mouse
(Neuro2a) NB cell lines, TT medullary thyroid cancer, PC12 neuroblastic tumors and normal pluripotent neural stem and
neural crest progenitors.pheochromocytoma, and human PC-3 prostate cancer cells
(Figure 2D). TrkA(I/II) without TrkAIII expression characterized
human A-549 nonsmall cell lung carcinoma and M14 melanoma TrkAIII exhibits spontaneous Tk and IP3K activities
Functional characterization of TrkAIII was made in direct com-cells, whereas human MDA-MB-231 breast cancer cells ex-
pressed neither TrkA(I/II) nor TrkAIII, confirming data from pri- parison with empty pcDNA3.1 vector, TrkAI, and Trk-T3 oncogene
(positive oncogenic control; Greco et al., 1995) stable transfectedmary tumors. In “normal” cell cultures, TrkA(I/II) and TrkAIII
coexpression characterized normal human neural stem cell neu- SH-SY5Y cells. Several clones were isolated by zeocin resis-
tance, and expression was confirmed by indirect immunofluo-rospheres, representing a very early developmental stage that
precedes neuronal, astroglial, or oligodendroglial lineage choice, rescence, immunoprecipitation/Western blotting (Figures 3A
and 3B), and RT-PCR (data not shown). Immunoprecipitationas well as mouse neural crest-derived TC-1S progenitor cells,
which can undergo either neurogenic or myogenic lineage of TrkA isoforms from stable transfectants identified 140 kDa
and 110 kDa TrkAI species, the latter representing differentiallychoice in response to external signals (Giannini et al., 2001).
In contrast, TrkA(I/II) without TrkAIII expression characterized glycosylated TrkAI (Martin-Zanca et al., 1989), a single 100 kDa
TrkAIII and a single 68 kDa Trk-T3 species, respectively (Figureprimary cultures of mouse cerebellar granule neurons (Figure
2D), displaying morphological features of neuronal differentia- 3B, left panel). Endogenous TrkAIII expression was not detected
in these blots due to the low lysate concentration and brevitytion (neurite extension) and expression of neuronal markers III-
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Figure 2. Human NBs, NB cells, and neural stem cells express TrkAIII
A: Southern blots of TrkA(I/II), TrkAIII, and GAPDH RT-PCR products from total RNAs (1 g) from different stage (I–IV) primary human NBs, hybridized with TrkA
exon 8 (upper panels), TrkA exon 6–7 (middle panels), or GAPDH probes (lower panels; asterisks denote Nmyc amplification).
B: Distribution (dots) and mean (horizontal line) densitometric TrkA(I/II)/TrkAIII ratios in Southern blots of NB samples grouped according to disease stage.
C: Southern blots of TrkAI and TrkAIII cDNAs (PCR) and TrkA(I/II), TrkAIII, and GAPDH RT-PCR products from human stage II and stage IV NBs; prostate (PrCa),
medullary thyroid (MTC), melanoma, pituitary, breast (Br), colon (Co), and stomach (St) tumors; fetal (Fe) and adult (Ad) brain; adrenal medulla (Ad Med)
and dorsal root ganglia (Drg); and normal breast (Br), colon (Co), and stomach (St) tissues.
D: Southern blots of TrkA(I/II), TrkAIII, and GAPDH RT-PCR products from human IMR-32, SH-SY5Y, SK-N-AS, KCNR, SK-N-SH (N and S), LA-N-5, SK-N-BE, and
mouse Neuro2a NB cells; neural crest-derived/related medullary thyroid (TT), pheochromocytoma (PC-12), prostate (PC-3), melanoma (M14); unrelated
lung carcinoma (A-549) and breast (MDA-MB-231) tumor cells; undifferentiated neural crest-derived progenitors (TC-1S) and neural stem cells (NSC); and
differentiated cerebellar granule neurons (CGN).
E: Immunofluorescent micrograph of differentiated cerebellar granule cell staining for the neuronal marker III-tubulin (red).
of the ECL reaction that is required to detect overexpressed higher IP3K activity than equivalent concentrations of TrkAI or
pcDNA control transfectant immunoprecipitates (Figure 3D).TrkA isoforms.
TrkAI and TrkAIII but not Trk-T3 exhibited membrane associ-TrkA isoforms immunoprecipitated from SH-SY5Y transfec-
ation in SH-SY5Y cells, assessed by immunoprecipitation oftants were assayed for constitutive tyrosine phosphorylation using
washed 100,000  g cell membrane fractions purified fromanti-TrkA phospho-tyrosine-specific antibodies. In contrast to
stable transfectants (data not shown). Transient transfection ofTrkAI, which did not exhibit spontaneous tyrosine residue phos-
myc-tagged TrkAIII into TrkAI stable transfectants followed byphorylation, TrkAIII and the Trk-T3 oncogene exhibited sponta-
anti-myc antibody immunoprecipitation did not result in TrkAIneous phosphorylation of tyrosines Y490, Y674/675, and Y785
pull-down, indicating that TrkAIII does not interact with TrkAI(Figure 3B), consistent with spontaneous receptor activity and
and implying that TrkAIII membrane association is not depen-
suggesting potential for signal transduction (Kaplan et al., 1991;
dent upon interaction with TrkAI (data not shown).
Obermeier et al., 1993a, 1993b, 1994; Meakin and Shooter,
1991; Meakin et al., 1999; Loeb et al., 1994; Segal et al., 1996; TrkAIII induces NF-B transcription factor activity
Cunningham et al., 1997). Spontaneous receptor activity associ- To confirm signal transduction from spontaneously active
ated with TrkAIII and Trk-T3 was confirmed by rabbit enolase TrkAIII, NF-	B transcription factor activity was assessed as a
Tk assay, which detected spontaneous Tk activity in similar transcriptional endpoint for IP3K/Akt signaling (Ozes et al.,
concentrations of immunoprecipitated TrkAIII and Trk-T3 but 1999). Electromobility shift assays (EMSAs) revealed enhanced
NF-	B site binding activity in nuclear extracts from TrkAIII andnot TrkAI (Figure 3C). Furthermore, TrkAIII and Trk-T3 exhibited
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Figure 3. TrkAIII is active and signals through IP/
Akt/NF-	B
A: Indirect immunofluorescence of TrkA isoform
expression in pcDNA, TrkAI, TrkAIII, and Trk-T3 SH-
SY5Y transfectants (scale bar, 50 m).
B: Western blots showing phospho-Y490, -Y674/
675, and -Y785 immunoreactivity of TrkA isoform
immunoprecipitates from untreated SH-SY5Y
transfectants.
C: 32P-rabbit enolase kinase assay showing eno-
lase (arrow) kinased by TrkAIII and Trk-T3 but not
TrkAI immunoprecipitates from SH-SY5Y transfec-
tants (relative isoform levels on right).
D: 32P-inositol kinase assay showing increased ki-
nased inositol levels (arrow) in TrkAIII and Trk-T3
compared to TrkA-I immunoprecipitates (middle
panel) (preimmune IgG controls are on the left;
relative isoform levels are on the right).
E: EMSA of specific NF-	B complexes (arrows) in
nontransfected (NT), pcDNA, TrkAI, TrkAIII, and
Trk-T3 SH-SY5Y transfectant nuclear extracts,
complex immunoreactivity to anti-p50 and -p65
but not cRel antibodies, and a competition
assay showing specific complex competition
(TrkAIII extracts only) by cold but not mutated
NF-	B (NF-	Bm) or nonspecific (NS) oligonucleo-
tides.
F: Histogram of reporter gene assays showing in-
creased NF-	B activity in TrkAIII and Trk-T3 com-
pared to nontransfected (NT), pcDNA, and TrkAI
stable SH-SY5Y transfectants and the inhibitory
effect of LY-294002 (LY), dominant-negative Akt
(dn-Akt), and dominant-negative I-	B (dn-I	B)
but not PD98059 (PD) on NF-	B reporter gene
activity in TrkAIII and Trk-T3 transfectants. Re-
sults are shown as mean (SD) luciferase activity
in three independent assays performed in du-
plicate.
Trk-T3, compared to pcDNA control and TrkAI transfectants TrkAIII binds Shc, p85, and PLC
but does not respond to NGF(Figure 3E). Specific NF-	B site binding complexes, which were
identified by competition assay in which 50-fold excess of unla- In contrast to TrkAI transfectants, which upon NGF treatment
(100 ng/ml for 10 min) exhibited induction of TrkAI Y490, Y674/beled NF-	B but not nonspecific competitor or mutated NF-	B
oligonucleotide competed for binding, contained both p65 and 675, and Y785 phosphorylation, the spontaneous tyrosine phos-
phorylation exhibited by TrkAIII and Trk-T3 was not affectedp50 proteins, determined using specific antibodies (Figure 3E,
TrkAIII transfectants only). NF-	B function in TrkAIII and Trk- by NGF (Figure 4A). NGF activation of TrkAI induced receptor
phospho Shc, Grb-2, Frs-2, p85, and PLC1 binding (FigureT3 transfectants was confirmed by NF-	B element luciferase
reporter gene assay (NF-	B LUC), which detected significantly 4B), consistent with reports that phosphorylated Y490, Y674/
675, and Y785 TrkA residues act as binding sites for signal-elevated activity in both (p  0.001), compared to pcDNA and
TrkAI transfectants (Figure 3F). NF-	B activity in TrkAIII and Trk- transducing adaptor proteins (Obermeier et al., 1993a, 1993b,
1994; Loeb et al., 1994; Segal et al., 1996; Meakin et al., 1999).T3 transfectants was significantly inhibited by the IP3K inhibitor
LY294002 (25 M for 24 hr) (p  0.001 for both), by dominant- In contrast to TrkAI, TrkAIII and Trk-T3 constitutively bound
nonphosphorylated Shc and p85, TrkAIII but not Trk-T3 boundnegative I	-B (Duffey et al., 1999) (p  0.001 for both) and by
K179M mutated Akt (Franke et al., 1995) (p  0.001 for both), PLC1, and neither isoform exhibited constitutive Grb-2 or Frs-2
binding (Figure 4B). NGF (100 ng/ml for 30 min) did not alterbut not by the MEK inhibitor PD98059 (2 M for 48 hr), con-
firming NF-	B, IP3K, and Akt but not Ras/MAPK involvement this pattern of binding to either TrkAIII or Trk-T3 (Figure 4B).
Thus, spontaneously active TrkAIII and TrkT3 bind signal-trans-(Figure 3F).
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Figure 4. TrkAIII binds Shc, PLC, and p85 and
does not respond to NGF
A: Western blots demonstrating phospho-Y490
(pY490), -Y674/675 (pY674/675), and -Y785
(pY785) immunoreactivity of TrkAI, TrkAIII, and Trk-
T3 immunoprecipitates from untreated (
) and
NGF-treated () (100 ng/ml for 10 min) SH-SY5Y
transfectants.
B: Western blot showing comparative differ-
ences in TrkA isoform association with Shc, Grb-2,
Frs-2, p85, and PLC-1 immunoprecipitates from
untreated (
) and NGF-treated () (100 ng/ml
for 30 min) SH-SY5Y transfectants.
C and D: Western blots demonstrating total
(lower panel) and active (upper panel) Ras lev-
els (C) and total (lower panel) and phosphory-
lated (upper panel) p44/p42 Erk1/2 levels (D) in
untreated (
) and NGF-treated () (100 ng/ml,
10 min for ras and 30 min for Erk) SH-SY5Y transfec-
tant extracts.
E: Phase contrast demonstration of NGF (100 ng/
ml for 48 hr) induction of neuritogenesis in TrkAI
but not TrkAIII SH-SY5Y transfectants (scale bar,
50 m).
F: MTS assays showing NGF (100 ng/ml) inhibition
of TrkAI (open triangle) but not TrkAIII (open cir-
cle), Trk-T3 (closed circle), or pcDNA (closed tri-
angle) SH-SY5Y transfectant proliferation over 3
days. Data are shown as mean absorbance at
492 nm in quadruplet cultures for each time (*p
0.05; **p  0.001; Student’s t test).
ducing adaptor proteins in a manner that differs from NGF- above low background levels in TrkAIII and TrkT3 transfectants,
further confirming lack of TrkAIII and Trk-T3 NGF respon-activated TrkAI and do not respond to NGF.
In a Ras binding domain pull-down assay, neither TrkAI, siveness (Figure 4D). NGF did not induce p38 phosphorylation
in any transfectant (data not shown). TrkAIII is devoid, therefore,TrkAIII, nor Trk-T3 transfectants exhibited above background
Ras activity, suggesting that within the context of SH-SY5Y of Ras/MAPK activating capacity even in the presence of NGF.
TrkAI gene transduction restores NGF responsiveness tocells spontaneously active TrkAIII and Trk-T3 do not activate Ras
(Figure 4C). Treatment with NGF (100 ng/ml for 10 min) stimulated NB cells, inducing growth arrest differentiation and/or apoptosis
(Matsushima and Bogenmann, 1990; Lavenius et al., 1995; Lu-above background Ras activity in TrkAI but not TrkAIII or Trk-T3
transfectants (Figure 4C), further confirming that neither TrkAIII carelli et al., 1997; Hallberg et al., 1998; Meakin et al., 1999;
Kolch, 2000; Edsjo et al., 2001; Sugimoto et al., 2001; Eggertnor Trk-T3 responds to NGF.
Phosphorylation of MAPK homologs p44/p42 Erk1/2 or p38 et al., 2002). In this study, NGF (100 ng/ml for 72 hr) induced
neuritogenesis in TrkAI but not in pcDNA control, TrkAIII, or Trk-is induced by Ras activation (Kolch, 2000). Consistent with an
incapacity to activate Ras, TrkAIII and Trk-T3 transfectants did T3 transfectants, none of which exhibited spontaneous neurito-
genesis in the absence of NGF (Figure 4E; only TrkAI and TrkAIIInot exhibit constitutive Erk1/2 or p38 phosphorylation (Figure
4D, Erk1/2 only). Furthermore, NGF (100 ng/ml for 30 min), are shown).
No significant difference in proliferation rate or doublingwhich induced relatively high-level p44/p42 Erk phosphorylation
in TrkAI transfectants, did not stimulate Erk phosphorylation time was observed between pcDNA, TrkAI, TrkAIII, and Trk-T3
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Figure 5. TrkAIII does not bind NGF but interferes
with NGF/TrkAI signaling
A: Cellular 125I-NGF binding assay demonstrating
mean (SD) cpm/50,000 cells 125I-NGF bound by
pcDNA, TrkAIII, TrkAI, and Trk-T3 SH-SY5Y transfec-
tants, in duplicate assays performed in triplicate.
B: Western blot of TrkAI and TrkAIII (upper panel),
phospho Y674/675 TrkA (second panel), phos-
pho p44/p42 Erk (third panel), and total Erk (bot-
tom panel) immunoreactivity in lysates (100 g/
lane) from TrkAI/pcDNA3.1 and TrkAI/TrkAIII SH-
SY5Y cotransfectants in the absence (Con) or
presence of NGF (100 ng/ml for 10 min).
C: MTS assay showing differences in TrkAI/pcDNA
and TrkAI/TrkAIII SH-SY5Y cotransfectant prolifer-
ation in the absence (open circles) or presence
(closed circles) of NGF (100 ng/ml), shown as
mean (SD) absorbance at 492 nm in dupli-
cated experiments performed in quadruplet.
D: Histogram of the effects of NGF (100 ng/ml)
on TrkAI/pcDNA (gray) and TrkAI/TrkAIII (white)
cotransfectant proliferation over 4 days, ex-
pressed as percentage (SD) difference in prolif-
eration compared to untreated controls (arbi-
trarily 100% for cell line at each time point) (*p 
0.05; **p  0.001; Student’s t test).
transfectants, determined by cell counting and MTS proliferation Erk phosphorylation in pcDNA/TrkAI but not TrkAIII/TrkAI co-
transfectants, indicating that TrkAIII interferes with NGF/TrkAIassay (data not shown). NGF (100 ng/ml for 1–3 days) signifi-
induction of Erk phosphorylation (Figure 5B).cantly inhibited the proliferation of TrkAI but not pcDNA, TrkAIII,
Because the MAPK/ERK pathway is involved in NGF/TrkAI-or Trk-T3 transfectants, determined by MTS assay (Figure 4F)
induced NB cell growth inhibition (Edsjo et al., 2001), we investi-(p  0.001 for all three time points). Therefore, spontaneously
gated the capacity of NGF to inhibit proliferation in pcDNA/active TrkAIII, unlike TrkAI, promotes neither SH-SY5Y differen-
TrkAI compared to TrkAIII/TrkAI cotransfectants. NGF (100tiation nor growth arrest in the absence or presence of NGF.
ng/ml) inhibited the proliferation of pcDNA/TrkAI cotransfec-
tants over a 4 day time course (Figure 5C; p  0.02 for all timeTrkAIII does not bind NGF and antagonizes
points), whereas TrkAIII/TrkAI cotransfectants exhibited alteredNGF/TrkAI signaling
behavior in response to NGF, which inhibited proliferation to aBecause TrkAIII does not respond to NGF, we examined its
significantly lesser extent from 1–3 days or not at all at 4 daysbinding capacity in a cellular 125I-NGF binding assay. In contrast
(Figures 5C and 5D).to TrkAI transfectants, which bound significantly more 125I-NGF
than pcDNA control transfectants (p  0.001), neither TrkAIII
TrkAIII protects SH-SY5Y cells from doxorubicin-nor Trk-T3 transfectants bound significantly more NGF than
induced deathpcDNA controls (Figure 5A), indicating that TrkAIII does not bind
TrkAIII induces Akt/NF-	B pathway activation, suggesting thatNGF in SH-SY5Y cells.
TrkAIII may protect SH-SY5Y cells from chemotherapy-inducedBecause TrkAI and TrkAIII display differences in signaling
apoptosis, as reported for BDNF/TrkB interaction in SH-SY5Y
and differ in ratio as a function of NB disease stage, we examined
cells (Jaboin et al., 2002). Indeed, TrkAIII expression significantly
whether TrkAIII may influence TrkAI-dependent cellular func- protected SH-SY5Y cells from doxorubicin-induced death,
tions. TrkAIII was transiently transfected into TrkAI stable SH- compared to pcDNA and TrkAI transfectants. Both pcDNA and
SY5Y transfectants, altering the TrkAI/TrkAIII ratio from almost TrkA-I transfectants exhibited similar reductions in viable cell
exclusively TrkAI to approximately 3 to 1 (Figure 5B). Under number 48 hr after treatment with 0.1 M (60%–62%), 0.5 M
these conditions, characterized by relatively lower levels of (76%–77%), and 1.0 M doxorubicin (84%–86%), whereas
TrkAIII compared to TrkAI expression, TrkAIII but not TrkAI ex- TrkAIII transfectants exhibited significantly increased resis-
hibited constitutive Y674/675 phosphorylation (Figure 5B). This tance: mean reductions in cell viability of 40% with 0.1 M,
suggests that receptor overexpression alone is unlikely to be 58% with 0.5 M, and 74% with 1.0 M doxorubicin were
responsible for spontaneous TrkAIII activation, by comparison recorded (p 0.05 for all three doses compared to either control
to TrkAI. Furthermore, TrkAIII did not induce phosphorylation or TrkAI transfectants) (data are shown in the text only).
of TrkAI (Figure 5B).
NGF (100 ng/ml) treatment of pcDNA/TrkAI (control) and TrkAIII transforms NIH3T3 cells and promotes
TrkAIII/TrkAI cotransfectants induced TrkAI Y674/675 phos- aggressive SH-SY5Y behavior
phorylation in both, indicating that TrkAIII does not interfere with TrkAIII oncogenic potential was assessed in transfected NIH3T3
fibroblasts. In contrast to control and TrkAI stable NIH3T3NGF activation of TrkAI (Figure 5B). In contrast, NGF induced
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Figure 6. TrkAIII transforms NIH-3T3 cells and pro-
motes aggressive SH-SY5Y behavior
A: Western blot demonstrating TrkAIII but not TrkAI
Y674/675 phosphorylation (right panel) in anti-
TrkA but not preimmune IgG immunoprecipitates
(left panel) from NIH-3T3 transfectants.
B: Phase contrast demonstration of soft agar
growth by TrkAIII but not control or stable TrkAI
NIH3T3 transfectants.
C: Tumorigenic activity exhibited by TrkAIII but
not control or TrkAI NIH-3T3 transfectants in nude
mice.
D: Phase contrast demonstration of increased
soft agar growth exhibited by TrkAIII and Trk-T3
compared to pcDNA and TrkAI SH-SY5Y transfec-
tants (scale bar, 1 mm).
E: Histogram of mean (SD) tumor volumes
(mm3) of xenograft tumors formed by TrkAIII
(closed circles), Trk-T3 (open squares), pcDNA
(closed squares), and TrkAI (open circles) SH-
SY5Y transfectants in nude mice over 13 days
(five animals per group, repeated twice).
F: Photographic demonstration of compara-
tive size differences of duplicate TrkAIII, Trk-T3,
pcDNA, and TrkAI transfectant-derived tumors
(day 13) (scale bar, 10 mm).
G: RT-PCR/Southern and IP/Western blots of TrkA
isoform expression in pcDNA, TrkAI, and TrkAIII SH-
SY5Y tumors in F.
transfectants, TrkAIII stable NIH3T3 transfectants exhibited 6D). In nude mice, TrkAIII and Trk-T3 SH-SY5Y transfectants
initiated tumor formation within 5 days (determined at a tumorconstitutive TrkAIII Y674/675 phosphorylation (Figure 6A),
formed large tumor-like spheroids in 14 day soft agar substrate- volume of 12 mm3), whereas pcDNA and TrkAI transfectants
did not initiate tumors for a further 2 days. Subsequent measure-independent growth assay (Figure 6B), and formed tumors
within 14 days of subcutaneous injection into nude mice (Figure ments at 7, 9, 11, and 13 days revealed significant differences
in tumor size for both TrkAIII and Trk-T3 versus pcDNA and6C), confirming TrkAIII oncogenic activity. Tumor formation was
considered at volumes above 12 mm3, and at 14 days TrkAIII TrkAI transfectants (Figure 6E; p  0.05 for both TrkAIII and
Trk-T3 tumors at all time points): mean tumor volumes recordedtransfectants produced tumors with a mean tumor volume of
116 mm3 (68.9). Neither control nor TrkAI transfectants pro- at sacrifice (13 days) were 526 89 mm3 in TrkAIII transfectants
(n  5), 354  60 mm3 in Trk-T3 transfectants (n  5), 225 duced tumors.
In SH-SY5Y cells, which already exhibit substrate-indepen- 60 mm3 in TrkAI transfectants (n  5), and 260  49 mm3 in
pcDNA3.1 transfectants (n  5) (Figure 6E). These differencesdent growth capacity and are tumorigenic in nude mice, both
TrkAIII and Trk-T3 stable transfection promoted the growth of are reflected in Figure 6F, demonstrating tumors in which TrkA
isoform expression was confirmed by RT-PCR, immunoprecipi-larger tumor-like spheroids in a 14 day soft agar substrate-
independent growth assay than either nontransfected (data not tation/Western blot (Figure 6G; Trk-T3 not shown), and immuno-
histochemistry (Figure 7A). Note that endogenous TrkAIII ex-shown) or pcDNA- or TrkAI-transfected counterparts (Figure
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Figure 7. TrkAIII increases tumor vascularity and
alters the angiogenic phenotype
A: Light micrographs of TrkA isoform, VEGF, and
GSI lectin neovascular staining in sections of 13
day pcDNA, TrkAIII, and TrkAI SH-SY5Y tumors
(scale bar, 100 m).
B: RT-PCR/Southern blot comparison of MMP-9,
VEGF, Tsp1, and GAPDH expression in duplicate
13 day pcDNA, TrkAIII, and TrkAI SH-SY5Y tumors.
C: RT-PCR/Southern blot comparison of steady-
state MMP-9, VEGF, Tsp1, TIMP-3, Ang1, and
GAPDH expression by pcDNA, TrkAIII, Trk-T3, and
TrkAI SH-SY5Y transfectants in vitro.
D and E: Western blot of MMP-9, MMP-2, and
p21VEGF (D) and ELISA of Tsp1 levels (E) in 48
hr serum-free conditioned medium from pcDNA,
TrkAIII, TrkT3, and TrkAI SH-SY5Y transfectants
in vitro.
F: RT-PCR/Southern blot showing the effects of
LY294002 (Ly) (25 M for 48 hr) on MMP-9, VEGF,
Tsp1, and GAPDH expression by pcDNA, TrkAIII,
and TrkAI transfectants in vitro.
pression was also detected in tumors derived from pcDNA and (mean vessel count of 12.9  5.42) (data in text only). Vessel
TrkAI transfectants (Figure 6G). counts did not significantly differ between pcDNA and TrkAI
tumors. This relative difference in tumor vascular density is re-
flected in Figure 7A, in which TrkA isoform, vascular lectin, andTrkAIII promotes tumor growth in association
VEGF staining are compared between representative pcDNA,with increased tumor vascularity and an altered
TrkAIII, and TrkAI transfectant-derived tumor sections. Thus,angiogenic phenotype
TrkAIII transfectants produce significantly more vascular tumorsConsistent with a potential role for angiogenesis in TrkAIII pro-
than control and TrkAI counterparts.motion of SH-SY5Y cell tumorigenicity, 13-day-old tumors from
RT-PCR assessment of angiogenic factor and inhibitor ex-TrkAIII transfectants exhibited a significantly elevated mean
pression in tumor extracts revealed an association between(SD) number of GSI-lectin-stained vessels per 40magnifica-
TrkAIII tumors and a relative increase in MMP-9 and VEGFtion microscopic tumor field (ten counts per tumor section) of
angiogenic factor expression and a relative decrease in the36.1 10.81 (p 0.001) when compared to 13-day-old pcDNA
(mean vessel count of 13.9  4.43) and TrkAI counterparts expression of the angiogenic inhibitor thrombospondin-1 (Tsp1),
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when compared to less vascular pcDNA and TrkAI tumor coun-
terparts (Figure 7B). A similar pattern of elevated MMP-9 and
VEGF but reduced Tsp1 expression, assessed by RT-PCR (Fig-
ure 7C), Western blot (Figure 7D), and ELISA (Figure 7E), charac-
terized TrkAIII and Trk-T3 compared to pcDNA and TrkAI SH-
SY5Y transfectants in vitro. TrkAIII and Trk-T3 transfectants also
exhibited a relative increase in Ang1 and decrease in TIMP-3
expression compared to control and TrkAI transfectants (Figure
7C), whereas no differences in Ang2, bFGF, MMP-2, TIMP-1,
or TIMP-2 expression were detected (data not shown).
Consistent with a potential role for IP3K but not Ras signaling
in TrkAIII regulation of the angiogenic phenotype, the IP3K inhib-
itor LY294002 (25 M for 48 hr), but not the MEK inhibitor
PD98059 (2 M for 48 hr), inhibited MMP-9 and VEGF expres-
sion but stimulated that of Tsp1 to a greater extent in TrkAIII
compared to pcDNA control and TrkAI transfectants (Figure 7F).
This implicates IP3K in regulation of the MMP-9/VEGF/Tsp1
equilibrium in SH-SY5Y cells and provides a mechanism by
which TrkAIII may alter the angiogenic phenotype.
TrkAIII expression is regulated by hypoxia
Hypoxia is an important epigenetic regulator of aggressive tu-
mor behavior, including NB (Harris, 2002; Jogi et al., 2002;
Pennacchietti et al., 2003). In this study, hypoxia induced by
CoCl2 (150 M for 24 hr) (Miyazaki et al., 2002) selectively in-
creased TrkAIII relative to TrkA(I/II) expression in human and
mouse NB cell lines (KCNR, SK-N-BE, SH-SY5Y, Neuro2a), PC-
12 pheochromocytoma, and TT medullary thyroid carcinoma
cells (Figure 8A) and stimulated TrkAIII relative to TrkAI protein
levels in SH-SY5Y cells (Figure 8B). Hypoxia did not enhance
TrkAIII expression by PC-3 prostate cells or induce expression
in TrkAIII-negative M14 melanoma, A-549 lung, and MDA-MB- Figure 8. Hypoxia stimulates TrkAIII expression in NB cells and neural pro-
231 breast tumor cells. Hypoxia stimulation of TrkAIII expression genitors
was also observed in undifferentiated human neural stem cells A: RT-PCR/Southern blot of normoxia (
) and hypoxia () effects on TrkA(I/
II), TrkAIII, and GAPDH expression by (upper panel) human KCNR, SK-N-BE,and neural crest-derived TC-1S progenitors, which exhibit con-
SH-SY5Y, and mouse Neuro2a NB cells, undifferentiated normal human neu-stitutive TrkAIII expression, whereas cerebellar granule cells dif-
ral stem cells (NSC), differentiated cerebellar granule neurons (CGN), and
ferentiating along the neuronal lineage (Figure 2E) were negative undifferentiated neural crest-derived progenitors (TC-1S); and (lower panel)
for TrkAIII expression even under hypoxic conditions (Figure neural crest-derived/related pheochromocytoma (PC-12), medullary thy-
roid cancer (TT), melanoma (M14), prostate cancer (PC-3), and nonneural8A). Therefore, hypoxia promotion of alternative TrkAIII splicing
related lung (A-549) and breast (MDA-MB-231) tumor cells.is restricted to NB, a subset of neural crest-derived tumor cells
B: IP/Western blot showing relative differences in TrkAIII and TrkA(I/II) expres-
and pluripotent early neural stem cells and neural crest progen- sion by SH-SY5Y cells cultured under normoxic (
) or hypoxic () conditions.
itors.
Discussion
TrkAIII expression characterizes neural stem cells
and an aggressive NB phenotypeIn this study, we unveil a hypoxia-regulated mechanism for
TrkAIII, cloned from SH-SY5Y NB cells and characterized as adetermining aggressive NB behavior characterized by a “switch”
novel splice variant in addition to TrkAI and TrkAII (Barker et
to alternative TrkA splicing and expression of a novel, constitu-
al., 1993), encodes a cell membrane-associated TrkA isoform
tively active, tumor-promoting TrkAIII variant that lacks exons with deletion of extracellular IG-C1 and related N-glycosylation
6, 7, and 9. TrkAIII, expressed at the expense of NGF-responsive domains of functional importance (Martin-Zanca et al., 1989;
TrkA receptors that promote NB cell differentiation and growth Watson et al., 1999; Arevalo et al., 2000) with an extracellular
arrest, exhibits spontaneous activity, induces chronic signal valine addition at the novel exon 5/8 splice junction.
transduction through IP/Akt but not Ras/MAPK, activates tran- TrkAIII identification raises questions concerning specificity
scription factor NF-	B, antagonizes NGF/TrkAI signaling, trans- of expression. In a variety of neural crest-derived and unrelated
forms NIH3T3 cells, and promotes aggressive NB cell behavior tumors and cell lines, TrkAIII exhibited relatively restricted ex-
associated with a more resistant and angiogenic phenotype, pression to NBs and, at a relatively low level, medullary thyroid
consistent with a potential oncogenic/tumor-promoting func- carcinoma, prostate tumors and cells, and pheochromocytoma
tion. Elevated TrkAIII expression in advanced stage NBs sug- cells, suggesting relative specificity for tumors and cells of neu-
ral crest origin or those that exhibit neuroendocrine featuresgests a potential role in NB pathogenesis.
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(Rumpold et al., 2002; Barakat et al., 2004). TrkAIII was also Meakin et al., 1999). It is unlikely that this reflects a malfunction
in postreceptor signaling, since NGF activated Ras/MAPK inexpressed by normal undifferentiated human neural stem cells
at a preneuronal astroglial and oligodendroglial developmental TrkAI transfectants in association with induction of phospho
Shc, Grb-2, or Frs-2 binding. Possible explanations includestage and murine neural crest-derived progenitors but not by
differentiation-committed cerebellar granule neurons; normal TrkAIII-associated IP3K activity below the Ras/MAPK activation
threshold (Hallberg et al., 1998) or direct inhibition of Raf-MEK-neural tissues including fetal and adult brain (probably reflecting
low stem cell content); dorsal root ganglia and adrenal medulla; ERK by constitutive IP/Akt signaling (Moelling et al., 2002). The
latter possibility is supported by TrkAIII antagonism of NGF/normal nonneural stomach, lung, colon, and breast tissues; or
normal fibroblasts. This suggests that expression is restricted TrkAI-induced Erk phosphorylation. Alternatively, reduced TrkAI
extracellular N-glycosylation alters membrane localization andto undifferentiated neural stem/crest progenitors but not cells
differentiated along the neuronal lineage (i.e., granule neurons) induces receptor but not Ras-MAPK activation (Watson et al.,
1999), suggesting that deletion of N-glycosylation domains fromor nonneural tissues and supports the possibility of a tissue-
specific rather than tumor-specific alternative splice mecha- TrkAIII may induce a similar activation.
The biological activity of TrkAIII differs dramatically fromnism, despite unavailability of normal human embryo neural
crest tissue, that within the tumor context may represent a stem/ that of TrkAI. TrkAI does not exhibit spontaneous ligand-inde-
pendent activity, is not oncogenic in NIH3T3 cells, and doesprogenitor cell condition related to a particular phase of neural
progenitor neoplastic transformation of relevance to NB, medul- not promote SH-SY5Y tumorigenic behavior, but it restores
NGF responsiveness, inducing differentiation and growth arrestlary thyroid cancer, and pheochromocytoma, which share neural
crest origin, and prostate cancer, which exhibits neural crest/ consistent with a potential antioncogenic role in NB (this study;
Matsushima and Bogenmann, 1990; Lavenius et al., 1995; Lu-neuroendocrine behavior (Rumpold et al., 2002; Barakat et al.,
2004). carelli et al., 1997; Hallberg et al., 1998; Meakin et al., 1999;
Kolch, 2000; Edsjo et al., 2001; Sugimoto et al., 2001; EggertIn NBs, TrkAIII expression varied as a ratio to other variants
as a function of disease stage and predominated in more high et al., 2002). In contrast, TrkAIII exhibits spontaneous activity
in SH-SY5Y cells but does not induce morphological differentia-stage (III and IV) than low stage (I and II) tumors, with a significant
increase in the TrkAIII/TrkA(I/II) expression ratio observed in tion or growth arrest and does not restore NGF responsiveness
to SH-SY5Y cells but promotes their tumorigenic behavior andcombined high stage (III and IV) compared to low stage (I and
II) NBs. This suggests that TrkAIII expression may be linked to is oncogenic in NIH3T3 cells. These differences reflect sponta-
neous TrkAIII but not TrkAI activity, TrkAIII signaling through IP/more aggressive NB behavior. Although this altered equilibrium
was statistically significant, greater numbers would be required Akt/NF-	B but not Ras/MAPK, and the incapacity of TrkAIII but
not TrkAI to bind and respond to NGF. Furthermore, TrkAIIIto firmly establish any potential prognostic value. Since most
approaches in the past would not have identified TrkAIII, our antagonizes NGF/TrkAI signaling and inhibition of NB cell prolif-
eration, which may help explain the NGF unresponsiveness ex-data are also in agreement with reports that low stage (I and II)
and a majority (over 60%) of advanced stage (III and IV) NBs hibited by many NB cell lines (Azar et al., 1990), and suggests
that altering the TrkAI/TrkAIII equilibrium in favor of TrkAIII mayexhibit high TrkAI expression, with low expression associated
with high stage Nmyc-amplified disease (Nakagawara et al., compromise antioncogenic NGF/TrkAI signals in NB. The onco-
genic activity exhibited by TrkAIII in NIH3T3 cells is supported1992; Nakagawara, 2001). Although RT-PCR detected TrkA in
all NB samples, three high stage Nmyc-amplified NBs exhibited by a report that engineered deletion of IG-C1 from rat TrkAI,
similar to naturally expressed TrkAIII, also induces oncogeniclow TrkAI expression, supporting this inverse relationship.
activation (Arevalo et al., 2000). However, TrkAIII is also ex-
pressed by nontumorigenic neural crest progenitors and neuralTrkAIII is a tumor promoter and antagonist
of antioncogenic NGF/TrkAI signaling stem cells, suggesting dependence for oncogenic activity upon
additional “cooperating” factors, despite being associatedIn SH-SY5Y cells, TrkAIII exhibits spontaneous activity (tyrosine
phosphorylation, Tk, and IP3K activity); interacts with known with anchorage-independent growth and a dedifferentiated phe-
notype.TrkA signal transducers Shc, PLC-, and the IP3K subunit p85
(Obermeier et al., 1993a, 1993b, 1994; Segal et al., 1996; Meakin Potential mechanisms through which TrkAIII promotes NB
cell tumorigenic behavior may include induction of a moreet al., 1999); and constitutively signals through IP3K/Akt but
not Ras/MAPK to activate the transcription factor NF-	B. It is stress-resistant phenotype, suggested by TrkAIII partial protec-
tion of SH-SY5Y cells from doxorubicin-induced death, whichunlikely that this spontaneous activity reflects enforced receptor
overexpression, reported to activate TrkAI in some cells (Lee is likely to involve IP/Akt/NFkB signaling (Jaboin et al., 2002),
and angiogenesis, suggested by the significantly increased vas-and Chao, 2001), since TrkAI activation did not occur under
similar conditions, and TrkAIII/TrkAI coexpression at an approxi- cularity exhibited by TrkAIII transfectant-derived tumors. This
was associated with an altered MMP-9/VEGF/Tsp-1 angiogenicmate ratio of 1 to 3 was accompanied by TrkAIII but not TrkAI
activation. It is more likely, therefore, that activation reflects equilibrium characterized by increased MMP-9 and VEGF but
reduced Tsp-1 expression. This equilibrium is emerging as anexon 6–7 omission, since IG-C1 and related N-glycosylation
domains, deleted in TrkAIII, prevent ligand-independent TrkAI important determinant of tumor angiogenesis, since MMP-9
triggers VEGF-mediated angiogenesis and Tsp-1 inhibits bothdimerization and activation (Watson et al., 1999; Arevalo et al.,
2000). MMP-9 activation and VEGF activity (Bergers et al., 2000; Rodri-
guez-Manzaneque et al., 2001). Inhibitor studies implicated IP3KTrkAIII induction of IP/Akt but not Ras/MAPK signaling in
SH-SY5Y cells is consistent with TrkAIII binding of p85 but in promoting high MMP-9 and VEGF but low Tsp1 expression
in SH-SY5Y cells, providing a mechanism through which TrkAIIInot phospho Shc, Grb-2, or Frs-2, which are required for NGF/
TrkAI activation of Ras/MAPK (this study; Hallberg et al., 1998; may exert its proangiogenic effect. The potential importance of
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tumor tissue (AmBion, Austin, TX); normal human fetal and adult brain andthis mechanism in NB pathogenesis is further supported by
adrenal medulla and dorsal root ganglia (Clontech, Palo Alto, CA); and experi-the relatively increased MMP-9 and VEGF but reduced Tsp-1
mental tumors and transfected cells were subjected to RT-PCR using primersexpression exhibited by advanced stage NBs (Ribatti et al.,
specific for TrkA; bFGF; VEGF; Tsp-1; Ang-1; Ang-2; MMP-9; TIMPs 1,
2001; Fakhari et al., 2002; Yang et al., 2003). 2, and 3; and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as
detailed in the Supplemental Data at http://www.cancercell.org/cgi/content/
Hypoxia promotes alternative TrkAIII splicing in neural full/6/4/347/DC1/.
progenitors and transformed counterparts
PCR analysis of genomic TrkA sequenceAlthough the molecular mechanisms that regulate alternative
Genomic SH-SY5Y DNA was subjected to PCR using TrkA-specific primersTrkAIII splicing remain to be elucidated, hypoxia was found to
spanning TrkA intron/exon 6 to the intron 7/exon splice junction and exon/stimulate alternative TrkAIII splicing in a variety of cell types,
intron 7 to exon 8/intron splice junction (Greco et al., 1996) and directly
including NB cells, a subset of neural crest-derived tumor cells sequenced in an ABI prism automated DNA sequencer, as detailed in the
(medullary thyroid and pheochromocytoma), normal neural stem Supplemental Data at http://www.cancercell.org/cgi/content/full/6/4/347/
DC1/.cells, and neural crest-derived progenitors but not in neural
crest-derived melanoma cells, differentiation-committed cere-
Proliferation assaybellar granule neurons, or a variety of nonneural normal (MRC-5
Cellular proliferation was determined using an MTS proliferation assay, asand NIH3T3 fibroblasts) or tumor (PC-3 prostate, A-549 lung,
directed by the manufacturer (Promega, Madison, WI) and detailed in the
MDA-MB-231 breast) cells. This suggests a possible hypoxia Supplemental Data at http://www.cancercell.org/cgi/content/full/6/4/347/
protection mechanism of potential physiological relevance to DC1/.
normal non-differentiation-committed neural/neural crest pro-
Immunoprecipitation and Western blotsgenitors that is lost upon differentiation commitment and absent
Immunoprecipitation and Western blots were performed on tumor and cellin unrelated tissues but conserved by transformed NB, medul-
extracts using appropriate immunoprecipitating antibodies or preimmunelary thyroid cancer, and pheochromocytoma counterparts, pos-
IgG and Protein G Sepharose (Fast flow, Sigma-Aldrich), as detailed in thesibly reflecting a stem/progenitor cell condition. Pathological
Supplemental Data at http://www.cancercell.org/cgi/content/full/6/4/347/
subversion of this mechanism by tumors may therefore provide DC1/.
a novel way for hypoxia to promote aggressive behavior, in
addition to Met-mediated invasive growth, dedifferentiation, and Stable transfections
Cells were stable transfected with pcDNA 3.1Zeo vectors bearing codingincreased angiogenesis (Harris, 2002; Jogi et al., 2002; Pennac-
TrkAI, TrkAIII, or Trk-T3 cDNAs or with empty vector using Lipofectaminechietti et al., 2003), and may help to explain, together with
as directed by the manufacturer (Invitrogen). Stable transfectants, isolateddedifferentiation, the increased TrkAIII expression exhibited by
by zeocin resistance, were clonally expanded and characterized as detailed
advanced stage NBs. in the Supplemental Data at http://www.cancercell.org/cgi/content/full/6/4/
In conclusion, we propose that alternative TrkA splicing, 347/DC1/.
which generates the novel TrkAIII variant, represents a regulated
tumor-promoting switch of relevance to NB. TrkAIII expression Nuclear extracts, EMSA, and luciferase reporter gene assays
Nuclear extracts were prepared, and EMSAs were performed as previouslythat is associated with a stem cell-like phenotype and promoted
described (Farina et al., 1999). Transient transfection of NF-	B luciferase andby tumor hypoxia would interfere with antioncogenic NGF/TrkAI
pRSVgal reporter genes was performed using Lipofectamine as directed bysignaling through Ras/MAPK, promote NGF-independent sig-
the manufacturer (Invitrogen), and -galactosidase assays (Farina et al.,
naling through IP/Akt, and induce a more stress-resistant, an- 1999) and luciferase assays are detailed in the Supplemental Data at http://
giogenic, and tumorigenic NB phenotype. A potential mecha- www.cancercell.org/cgi/content/full/6/4/347/DC1/.
nism for regulating NB progression based on alternative TrkAIII
splicing rather than genetic TrkA abnormality would theoretically Growth in soft agar, tumor growth in nude mice,
and tumor histologypermit reversal by reestablishing regular TrkA (I/II) splicing,




Cell cultures were incubating for up to 24 hr with 150 M CoCl2 in completeComplete details of all cell lines, reagents, and experimental procedures
medium, as previously described (Miyazaki et al., 2002).used are presented as Supplemental Data at http://www.cancercell.org/cgi/
content/full/6/4/347/DC1/.
Rabbit enolase TK, inositol IP3K, and Ras activity assays
Tk and IP3K assays were performed as previously described (Meakin andTrkA isoform cDNA cloning
Shooter, 1991; Obermeier et al., 1993b), and Ras activation assays wereBriefly, purified mRNA from SH-SY5Y cells was subjected to RT-PCR using
performed using a Ras activity kit as directed by the manufacturer (Upstatethe TrkA-specific primers 5-ATGCTGCGAGGCGGACGGCGC-3 and 5-
Biotech, Lake Placid, NY), as detailed in the Supplemental Data at http://CTAGCCCAGGACATCCAGGTA-3, which span the complete human TrkAI
www.cancercell.org/cgi/content/full/6/4/347/DC1/.cDNA coding sequence. Products were gel purified, cloned into TA PCR
cloning vectors, and sequenced using an ABI prism automated DNA se-
Cellular 125I-NGF binding assayquencer, and intact cDNAs were subcloned into pcDNA3.1 mammalian ex-
Steady-state binding studies with 125I-NGF were performed as previouslypression vectors (detailed methods are presented as Supplemental Data at
described (Mahadeo et al., 1994) and are detailed in the Supplemental Datahttp://www.cancercell.org/cgi/content/full/6/4/347/DC1/).
at http://www.cancercell.org/cgi/content/full/6/4/347/DC1/.
RT-PCR/Southern blotting
Total RNAs (1 g) from primary human NBs (tissue bank of the Italian Associ- Statistical analysis
Mann-Whitney and Student’s t tests were employed to provided values withation of Haematology and Pediatric Oncology, Genoa, Italy); pituitary, pros-
tate, melanoma, and medullary thyroid tumors (Department of Pathology associated probabilities, considered to be statistically significantly if less
than 0.05, by convention.University of Rome, Italy); matched normal and breast, colon, and stomach
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